Skip to main content
. 2022 Feb 14;9(6):ofac079. doi: 10.1093/ofid/ofac079

Table 2.

Clinical Outcome of Patients Who Received Ceftolozane/Tazobactam and Those Who Received the Standard of Care

Clinical Outcome Ceftolozane/Tazobactam
(n = 47)
Standard of Care
(n = 50)
P Value
Clinical outcome at EOIV .10
 Favorable clinical response 41 (87) 36 (72)
 Clinical failure 2 (4) 9 (18)
 ndeterminate 4 (9) 5 (10)
Clinical outcome at TOC .01
 Clinical cure 34 (72) 28 (56)
 Clinical failure 3 (6) 15 (30)
 Indeterminate 10 (21) 7 (14)
Clinical outcome at LFU .028
 Clinical cure 33 (70) 26 (52)
 Clinical failure 4 (9) 15 (30)
 Indeterminate 10 (21) 9 (18)
Mortality during the study 3 (6) 2 (4) .67
Duration between last dose of study drug and death, d, median (range) 17 (15–34) 29 (28–29) .77
Infection-related mortality 0 (0) 0 (0)
30-d all-cause mortality 2 (4) 2 (4) >.99

Data are presented as No. of patients (%) unless otherwise specified.

Abbreviations: EOIV, end of intravenous therapy; LFU, late follow-up; TOC, test of cure.